| 英文名稱 |
中文名稱 |
CAS號(hào) |
操作 |
| PH 797804, (±)- - rac-PH 797804 | rac-PH 797804 |
PH-797804 |
586379-66-0 |
詳細(xì)
|
| PHA 408 |
PHA 408 |
503555-55-3 |
詳細(xì)
|
| PHA-767491 |
PHA767491 |
845714-00-3 |
詳細(xì)
|
| PHT 427 |
4-十二烷基-N-1,3,4-噻二唑-2-基苯磺酰胺 |
1191951-57-1 |
詳細(xì)
|
| PI 103 hydrochloride |
PI-103 (Hydrochloride) |
371935-79-4 |
詳細(xì)
|
| PIK 75 hydrochloride |
2-甲基-5-硝基苯磺酸 (2E)-2-[(6-溴咪唑并[1,2-A]吡啶-3-基)亞甲基]-1-甲酰肼 |
945619-31-8 |
詳細(xì)
|
| PIK 90 |
N-(2,3-二氫-7,8-二甲氧基咪唑并[1,2-C]喹唑啉-5-基)-3-吡啶甲酰胺 |
677338-12-4 |
詳細(xì)
|
| Piperlongumine - Piplartine |
蓽茇酰胺 |
20069-09-4 |
詳細(xì)
|
| PKG drug G1 |
374703-78-3 |
374703-78-3 |
詳細(xì)
|
| PKI 587 - PF 05212384 |
N-[4-[[4-(二甲基氨基)-1-哌啶基]羰基]苯基]-N'-[4-[4,6-二(4-嗎啉基)-1,3,5-三嗪-2-基]苯基]脲 |
1197160-78-3 |
詳細(xì)
|
| PluriSIn #1 - NSC 14613 | Pluripotent cell-specific inhibitor #1 |
NSC 14613 |
91396-88-2 |
詳細(xì)
|
| PLX 4032 - RG 7204 | Vemurafenib | RO 5185426 |
維羅非尼 |
918504-65-1 |
詳細(xì)
|
| PLX 4720 |
N-[3-[(5-氯-1H-吡咯并[2,3-B]吡啶-3-基)羰基]-2,4-二氟苯基]-1-丙磺酰胺 |
918505-84-7 |
詳細(xì)
|
| PND 1186 - SR 2516 | VS 4718 |
PND1186 |
1061353-68-1 |
詳細(xì)
|
| PNU 100480 - PF 02341272 | U 100480 | Sutezolid |
PF-02341272 |
168828-58-8 |
詳細(xì)
|
| Posaconazole - SCH 56592 | Noxafil |
泊沙康唑 |
171228-49-2 |
詳細(xì)
|
| PPP hydrochloride |
|
21602-56-2 |
詳細(xì)
|
| Pravadoline - WIN 48098 |
普拉朵林 |
92623-83-1 |
詳細(xì)
|
| PRMT3 inhibitor 1 - Compound 1 |
|
1340875-03-7 |
詳細(xì)
|
| PRT 4165 - NSC 600157 |
PRT4165 |
31083-55-3 |
詳細(xì)
|
| PS 1145 |
PS-1145 |
431898-65-6 |
詳細(xì)
|
| PS 47 |
PS47;PS 47 |
1180676-33-8 |
詳細(xì)
|
| PS 48 |
(Z)-5-(4-氯苯基)-3-苯基戊-2-烯酸 |
1180676-32-7 |
詳細(xì)
|
| PTIQ |
PTIQ |
1032822-42-6 |
詳細(xì)
|
| PU-H71 trihydrochloride |
|
2108826-10-2 |
詳細(xì)
|
| PXS 4728A - PXS 4728 HCl |
PXS 4728A |
1478364-68-9 |
詳細(xì)
|
| Pyroxamide |
N-羥基-N'-3-吡啶基辛二酰胺 |
382180-17-8 |
詳細(xì)
|
| R 406 |
R-406 |
841290-80-0 |
詳細(xì)
|
| R 547 |
[4-氨基-2-[(1-甲磺?；哙?4-基)氨基]嘧啶-5-基](2,3-二氟-6-甲氧基苯基)甲酮 |
741713-40-6 |
詳細(xì)
|
| RAD51 inhibitor B02 |
RAD51 INHIBITOR B02 |
1290541-46-6 |
詳細(xì)
|
| RAF709 |
化合物RAF709 |
1628838-42-5 |
詳細(xì)
|
| Rapamycin - Sirolimus |
雷帕霉素 |
53123-88-9 |
詳細(xì)
|
| PFM01 |
PFM01 |
1558598-41-6 |
詳細(xì)
|
| RBC 8 |
RBC8 |
361185-42-4 |
詳細(xì)
|
| Rbin-1 - Ribozinoindole-1 |
RBIN-1 |
328023-11-6 |
詳細(xì)
|
| Rbin-2 - Ribozinoindole-2 |
Rbin-2 - Ribozinoindole-2 |
2032282-97-4 |
詳細(xì)
|
| Regorafenib - BAY 73-4506 | Stivarga |
瑞格非尼 |
755037-03-7 |
詳細(xì)
|
| Remodelin |
REMODELIN |
949912-58-7 |
詳細(xì)
|
| REP 3123 dihydrochloride - CRS3123 dihydrochloride |
REP 3123 DIHYDROCHLORIDE |
1013915-99-5 |
詳細(xì)
|
| REP 8839 |
貝得羅星 |
757942-43-1 |
詳細(xì)
|
| Reversine |
REVERSINE |
656820-32-5 |
詳細(xì)
|
| RG 108 |
RG108 |
48208-26-0 |
詳細(xì)
|
| RGFP 966 |
RGFP966 |
1357389-11-7 |
詳細(xì)
|
| RI-1 |
3-氯-1-(3,4-二氯苯基)-4-(4-嗎啉基)-1H-吡咯-2,5-二酮 |
415713-60-9 |
詳細(xì)
|
| Rigosertib sodium - ON01910 sodium | Estybon |
瑞格色替鈉 |
592542-60-4 |
詳細(xì)
|
| RIPA-56 |
RIPA-56 |
1956370-21-0 |
詳細(xì)
|
| RITA - NSC 652287 |
5,5'-(2,5-呋喃二基)二-2-噻吩甲醇 |
213261-59-7 |
詳細(xì)
|
| RKI 1447 |
1-(3-羥基芐基)-3-(4-(吡啶-4-基)噻唑-2-基)脲 |
1342278-01-6 |
詳細(xì)
|
| RO 28-0450 - RO 28-1675, (±)- |
3-CYCLOPENTYL-2-(4-METHANESULFONYL-PHENYL)-N-THIAZOL-2-YL-PROPIONAMIDE |
300352-96-9 |
詳細(xì)
|
| RO 28-1674 - RO 28-0450, (S)- |
|
599164-57-5 |
詳細(xì)
|
| RO 28-1675 - RO 28-0450, (R)- |
(2R)-3-環(huán)戊基-2-[4-(甲基磺?；?苯基]-N-(噻唑-2-基)丙酰胺 |
300353-13-3 |
詳細(xì)
|
| RO 3306 |
2-[[(噻吩-2-基)甲基]氨基]-5-[1-(喹啉-6-基)甲-(Z)-亞基]噻唑-4-酮 |
872573-93-8 |
詳細(xì)
|
| RO 4929097 |
N1-[(7S)-6,7-二氫-6-氧代-5H-二苯并[B,D]氮雜卓-7-基]-2,2-二甲基-N3-(2,2,3,3,3-五氟丙基)丙二酰胺 |
847925-91-1 |
詳細(xì)
|
| RO 61-8048 |
RO 61-8048 |
199666-03-0 |
詳細(xì)
|
| Roflumilast - Daxas | BY 217 | BYK 20869 | B 9302-107 |
羅氟司特 |
162401-32-3 |
詳細(xì)
|
| PF 06260933 dihydrochloride |
PF 06260933 dihydrochloride |
1883548-86-4 |
詳細(xì)
|
| PF 06447475 |
PF-06447475 |
1527473-33-1 |
詳細(xì)
|
| PF 06463922 - Lorlatinib |
勞拉替尼 |
1454846-35-5 |
詳細(xì)
|
| PF 06465469 |
PF 06465469
Discontinued See A191400 |
1407966-77-1 |
詳細(xì)
|
| PF 3845 |
PF 3845 |
1196109-52-0 |
詳細(xì)
|
| PF 431396 |
N-甲基-N-[2-[[[2-[(2-氧代-2,3-二氫-1H-吲哚-5-基)氨基]-5-三氟甲基嘧啶-4-基]氨基]甲基]苯基]甲磺酰胺 |
717906-29-1 |
詳細(xì)
|
| PF 4693627 - PF 04693627 |
PF-4693627 |
1312815-93-2 |
詳細(xì)
|
| PF 4708671 - PF 04708671 |
PF-4708671 |
1255517-76-0 |
詳細(xì)
|
| PF 477736 - PF 00477736 |
PF 477736 |
952021-60-2 |
詳細(xì)
|
| PF 4800567 |
PF 4800567 |
1188296-52-7 |
詳細(xì)
|
| PF 543 citrate |
(2R)-1-[[4-[[3-甲基-5-[(苯磺?；?甲基]苯氧基]甲基]苯基]甲基]-2-吡咯烷甲醇檸檬酸鹽 |
1415562-83-2 |
詳細(xì)
|
| PF 573228 |
6-[(4-((3-(甲磺?；?芐基)氨基)-5-三氟甲基嘧啶-2-基)氨基]-3,4-二氫-1H-喹啉-2-酮 |
869288-64-2 |
詳細(xì)
|
| PF 956980 |
PF-956980 |
1262832-74-5 |
詳細(xì)
|
| PFK 158 |
PFKFB3抑制劑(PFK-158) |
1462249-75-7 |
詳細(xì)
|
| Rolipram |
諾普利蘭 |
61413-54-5 |
詳細(xì)
|
| Rolipram, (R)-(-)- |
(4R)-4-[3-(環(huán)戊氧基)-4-甲氧基苯基]吡咯-2-酮 |
85416-75-7 |
詳細(xì)
|
| Rolipram, (S)-(+)- |
S- (+)-Rolipram |
85416-73-5 |
詳細(xì)
|
| RS-1 - RAD51-Stimulatory Compound-1 |
4-溴-N-(4-溴苯基)-3-[[(苯基甲基)氨基]磺?；鵠苯甲酰胺 |
312756-74-4 |
詳細(xì)
|
| RU-SKI 43 hydrochloride |
Hhat Inhibitor |
|
詳細(xì)
|
| RUSKI-201 dihydrochloride |
化合物 RUSKI-201 DIHYDROCHLORIDE |
|
詳細(xì)
|
| Ruxolitinib - INCB 018424 phosphate |
魯索利替尼磷酸鹽 |
1092939-17-7 |
詳細(xì)
|
| S3QEL 2 |
S3QEL 2 |
890888-12-7 |
詳細(xì)
|
| Salermide |
CS-2458 |
1105698-15-4 |
詳細(xì)
|
| Santacruzamate A - CAY 10683 |
HDAC抑制劑 |
1477949-42-0 |
詳細(xì)
|
| SAR405 |
CS-2552 |
1523406-39-4 |
詳細(xì)
|
| SAR405838 - MI-77301 |
SAR 405838 |
1303607-60-4 |
詳細(xì)
|
| SB 202190 |
4-(4-氟苯基)-2-(4-羥基苯基)-5-(4-吡啶基)-1H-咪唑 |
152121-30-7 |
詳細(xì)
|
| SB 203580 |
4-(4-氟苯基)-2-(4-甲基亞磺?；交?-5-(4-吡啶基)-1H-咪唑 |
152121-47-6 |
詳細(xì)
|
| SB 203580 hydrochloride |
SB 203580鹽酸鹽 |
869185-85-3 |
詳細(xì)
|
| SB 207499 - Cilomilast | Ariflo |
西洛司特 |
153259-65-5 |
詳細(xì)
|
| SB 216763 |
SB216763 |
280744-09-4 |
詳細(xì)
|
| SB 590885 |
5-[2-[4-[2-(二甲基氨基)乙氧基]苯基]-5-(4-吡啶基)-1H-咪唑-4-基]-2,3-二氫-1-茚酮肟 |
405554-55-4 |
詳細(xì)
|
| SB 706504 - PCG |
化合物 T23327 |
911110-38-8 |
詳細(xì)
|
| PF 05081090 - PF 5081090 |
PF5081090 |
1312473-63-4 |
詳細(xì)
|
| SB 747651A - SB 747651 tetrahydrochloride |
|
|
詳細(xì)
|
| SB 939 - Pracinostat |
(2E)-3-[2-丁基-1-[2-(二乙基氨基)乙基]-1H-苯并咪唑-5-基]-N-羥基丙烯酰胺 |
929016-96-6 |
詳細(xì)
|
| PDK1 inhibitor 2610 |
|
2108463-93-8 |
詳細(xì)
|
| Perifosine - KRX 0401 | D 21266 |
哌立福辛 |
157716-52-4 |
詳細(xì)
|
| PF 00356231 |
化合物PF 00356231 |
766536-21-4 |
詳細(xì)
|
| PF 02341066 - Crizotinib | PF 2341066 |
克唑替尼 |
877399-52-5 |
詳細(xì)
|
| PF 03814735 |
N-[2-[(1S,4R)-6-[[4-(環(huán)丁基氨基)-5-(三氟甲基)-2-嘧啶基]氨基]-1,2,3,4-四氫萘-1,4-亞氨-9-基]-2-氧代乙基]乙酰胺 |
942487-16-3 |
詳細(xì)
|
| PF 04447943 - PF 4447943 |
PF 4447943 |
1082744-20-4 |
詳細(xì)
|
| PF 04691502 |
2-氨基-8-[反式-4-(2-羥基乙氧基)環(huán)己基]-6-(6-甲氧基-3-吡啶基)-4-甲基吡啶并[2,3-D]嘧啶-7(8H)-酮 |
1013101-36-4 |
詳細(xì)
|
| PF 04859989 hydrochloride - L-3-Amino-3,4-dihydro-1-hydroxycarbstyril hydrochloride |
(S)-3-aMino-1-hydroxy-3,4-dihydroquinolin-2(1H)-one hydrochloride |
177943-33-8 |
詳細(xì)
|
| PF 04981517 - CYP3cide | PF 4981517 |
PF-4981517 |
1390637-82-7 |
詳細(xì)
|